Business Context and Reporting Period
This Form 6-K filing by BioBlast Pharma Ltd. (also referred to as Enlivex Ltd. in metadata) covers the month of January 2016. The registrant is a foreign private issuer based in Tel Aviv, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notice of a corporate governance event rather than a financial results announcement.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this document. The primary content is the incorporation by reference of the Notice of Meeting, Proxy Statement, and Proxy Card for an Extraordinary General Meeting of Shareholders.
Guidance, Outlook, and Corporate Actions
- Shareholder Meeting: An Extraordinary General Meeting is scheduled for Wednesday, February 24, 2016.
- Record Date: Only shareholders of record holding Ordinary Shares (nominal value NIS 0.01) at the close of trading on the Nasdaq Global Market on January 25, 2016, are entitled to notice and vote.
- Registration Statements: The proxy materials are incorporated by reference into the registrant's Form F-3 (File No. 333-206032) and Form S-8 (File No. 333-203114) registration statements.
Key Facts for Investor Verification
- Verify the specific agenda items for the Extraordinary General Meeting in the attached Exhibit 99.1 (Proxy Statement), as they are not detailed in the cover letter.
- Confirm the record date of January 25, 2016, to determine voting eligibility.
- Review the referenced Form F-3 and Form S-8 filings for details on potential capital raises or equity compensation plans associated with this meeting.